Literature DB >> 21788134

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.

Brent D G Page1, Steven Fletcher, Peibin Yue, Zhihua Li, Xiaolei Zhang, Sumaiya Sharmeen, Alessandro Datti, Jeffrey L Wrana, Suzanne Trudel, Aaron D Schimmer, James Turkson, Patrick T Gunning.   

Abstract

Signal transducer and activator of transcription 3 (Stat3) protein is a cytosolic transcription factor that is aberrantly activated in numerous human cancers. Inhibitors of activated Stat3-Stat3 protein complexes have been shown to hold therapeutic promise for the treatment of human cancers harboring activated Stat3. Herein, we report the design and synthesis of a focused library of salicylic acid containing Stat3 SH2 domain binders. The most potent inhibitor, 17o, effectively disrupted Stat3-phosphopeptide complexes (K(i)=13 μM), inhibited Stat3-Stat3 protein interactions (IC(50)=19 μM) and silenced intracellular Stat3 phosphorylation and Stat3-target gene expression profiles. Inhibition of Stat3 function in both breast and multiple myeloma (MM) tumor cells correlated with induced cell death (EC(50)=10 and 16 μM, respectively).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788134      PMCID: PMC4530782          DOI: 10.1016/j.bmcl.2011.06.056

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Design, synthesis, and studies of small molecule STAT3 inhibitors.

Authors:  Deepak Bhasin; Katryna Cisek; Trupti Pandharkar; Nicholas Regan; Chenglong Li; Bulbul Pandit; Jiayuh Lin; Pui-Kai Li
Journal:  Bioorg Med Chem Lett       Date:  2007-10-17       Impact factor: 2.823

Review 2.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Authors:  Stephen Y Lai; Faye M Johnson
Journal:  Drug Resist Updat       Date:  2010-05-14       Impact factor: 18.500

3.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

4.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

5.  Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.

Authors:  Steven Fletcher; Brent D G Page; Xialoei Zhang; Peibin Yue; Zhi Hua Li; Sumaiya Sharmeen; Jagdeep Singh; Wei Zhao; Aaron D Schimmer; Suzanne Trudel; James Turkson; Patrick T Gunning
Journal:  ChemMedChem       Date:  2011-05-25       Impact factor: 3.466

6.  Identification of a New Series of STAT3 Inhibitors by Virtual Screening.

Authors:  Kenji Matsuno; Yoshiaki Masuda; Yutaka Uehara; Hiroshi Sato; Ayumu Muroya; Osamu Takahashi; Takane Yokotagawa; Toshio Furuya; Tadashi Okawara; Masami Otsuka; Naohisa Ogo; Tadashi Ashizawa; Chie Oshita; Sachiko Tai; Hidee Ishii; Yasuto Akiyama; Akira Asai
Journal:  ACS Med Chem Lett       Date:  2010-07-13       Impact factor: 4.345

7.  Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.

Authors:  Steven Fletcher; Jagdeep Singh; Xiaolei Zhang; Peibin Yue; Brent D G Page; Sumaiya Sharmeen; Vijay M Shahani; Wei Zhao; Aaron D Schimmer; James Turkson; Patrick T Gunning
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

8.  A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.

Authors:  Xiaolei Zhang; Peibin Yue; Steven Fletcher; Wei Zhao; Patrick T Gunning; James Turkson
Journal:  Biochem Pharmacol       Date:  2010-01-11       Impact factor: 5.858

9.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Authors:  D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

10.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.

Authors:  James Turkson; Joon S Kim; Shumin Zhang; Jing Yuan; Mei Huang; Matthew Glenn; Eric Haura; Said Sebti; Andrew D Hamilton; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

View more
  20 in total

1.  Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Authors:  Carolyn C Arpin; Stephen Mac; Yanlin Jiang; Huiwen Cheng; Michelle Grimard; Brent D G Page; Malgorzata M Kamocka; Sina Haftchenary; Han Su; Daniel P Ball; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Rahul Rana; Helmut Hanenberg; Kagan Kerman; Kyle C McElyea; George E Sandusky; Patrick T Gunning; Melissa L Fishel
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.

Authors:  Azadeh Arabzadeh; Jeremy Dupaul-Chicoine; Valérie Breton; Sina Haftchenary; Sara Yumeen; Claire Turbide; Maya Saleh; Kevin McGregor; Celia M T Greenwood; Uri David Akavia; Richard S Blumberg; Patrick T Gunning; Nicole Beauchemin
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

3.  Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.

Authors:  Sina Haftchenary; Andriana O Jouk; Isabelle Aubry; Andrew M Lewis; Melissa Landry; Daniel P Ball; Andrew E Shouksmith; Catherine V Collins; Michel L Tremblay; Patrick T Gunning
Journal:  ACS Med Chem Lett       Date:  2015-07-22       Impact factor: 4.345

4.  Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.

Authors:  Sara Pedron; Gabrielle L Wolter; Jee-Wei E Chen; Sarah E Laken; Jann N Sarkaria; Brendan A C Harley
Journal:  Biomaterials       Date:  2019-07-19       Impact factor: 12.479

5.  Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

Authors:  Sina Haftchenary; H Artee Luchman; Andriana O Jouk; Anthony J Veloso; Brent D G Page; Xin Ran Cheng; Sean S Dawson; Natalie Grinshtein; Vijay M Shahani; Kagan Kerman; David R Kaplan; Carly Griffin; Ahmed M Aman; Rima Al-Awar; Samuel Weiss; Patrick T Gunning
Journal:  ACS Med Chem Lett       Date:  2013-09-08       Impact factor: 4.345

6.  Anticancer activity and SAR studies of substituted 1,4-naphthoquinones.

Authors:  Deepak Bhasin; Somsundaram N Chettiar; Jonathan P Etter; May Mok; Pui-Kai Li
Journal:  Bioorg Med Chem       Date:  2013-05-18       Impact factor: 3.641

7.  Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors.

Authors:  Matthew B Minus; Haopei Wang; Jaime O Munoz; Alexandra M Stevens; Alicia E Mangubat-Medina; Michael J Krueger; Wei Liu; Moses M Kasembeli; Julian C Cooper; Mikhail I Kolosov; David J Tweardy; Michele S Redell; Zachary T Ball
Journal:  Org Biomol Chem       Date:  2020-05-06       Impact factor: 3.876

8.  A single diamagnetic catalyCEST MRI contrast agent that detects cathepsin B enzyme activity by using a ratio of two CEST signals.

Authors:  Dina V Hingorani; Luis A Montano; Edward A Randtke; Yeon Sun Lee; Julio Cárdenas-Rodríguez; Mark D Pagel
Journal:  Contrast Media Mol Imaging       Date:  2015-12-03       Impact factor: 3.161

9.  Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.

Authors:  Diana Resetca; Sina Haftchenary; Patrick T Gunning; Derek J Wilson
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

10.  Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.

Authors:  Matthew B Minus; Wei Liu; Farrukh Vohidov; Moses M Kasembeli; Xin Long; Michael J Krueger; Alexandra Stevens; Mikhail I Kolosov; David J Tweardy; Edward Allan R Sison; Michele S Redell; Zachary T Ball
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-07       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.